Pacira BioSciences Future Growth

Future criteria checks 3/6

Pacira BioSciences is forecast to grow earnings and revenue by 59.1% and 0.6% per annum respectively. EPS is expected to grow by 55.3% per annum. Return on equity is forecast to be 6.9% in 3 years.

Key information

59.1%

Earnings growth rate

55.3%

EPS growth rate

Pharmaceuticals earnings growth	23.9%
Revenue growth rate	0.6%
Future return on equity	6.9%
Analyst coverage	Good
Last updated	05 Dec 2024

Recent future growth updates

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Recent updates

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Nov 25

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Sep 06

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Jul 23

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

Earnings and Revenue Growth Forecasts

NasdaqGS:PCRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	659	90	169	173	8
12/31/2025	675	55	152	186	8
12/31/2024	694	-5	140	153	8
9/30/2024	695	-91	194	204	N/A
6/30/2024	690	64	185	194	N/A
3/31/2024	682	70	173	185	N/A
12/31/2023	675	42	139	155	N/A
9/30/2023	666	7	130	149	N/A
6/30/2023	669	-5	127	147	N/A
3/31/2023	669	-10	105	134	N/A
12/31/2022	667	16	115	145	N/A
9/30/2022	654	21	93	126	N/A
6/30/2022	614	39	102	144	N/A
3/31/2022	580	38	104	144	N/A
12/31/2021	542	42	80	126	N/A
9/30/2021	513	62	98	149	N/A
6/30/2021	503	174	83	129	N/A
3/31/2021	443	148	39	83	N/A
12/31/2020	430	146	39	77	N/A
9/30/2020	421	126	28	56	N/A
6/30/2020	408	-10	13	35	N/A
3/31/2020	435	0	58	73	N/A
12/31/2019	421	-11	60	71	N/A
9/30/2019	394	2	58	66	N/A
6/30/2019	372	8	53	64	N/A
3/31/2019	354	7	44	55	N/A
12/31/2018	337	0	34	49	N/A
9/30/2018	321	-4	27	45	N/A
6/30/2018	305	-11	N/A	25	N/A
3/31/2018	292	-33	N/A	15	N/A
12/31/2017	287	-43	N/A	18	N/A
9/30/2017	280	-51	N/A	18	N/A
6/30/2017	281	-66	N/A	33	N/A
3/31/2017	280	-54	N/A	37	N/A
12/31/2016	276	-38	N/A	33	N/A
9/30/2016	273	-36	N/A	33	N/A
6/30/2016	267	-11	N/A	26	N/A
3/31/2016	256	-3	N/A	26	N/A
12/31/2015	249	2	N/A	28	N/A
9/30/2015	241	10	N/A	26	N/A
6/30/2015	231	4	N/A	29	N/A
3/31/2015	219	-1	N/A	30	N/A
12/31/2014	198	-14	N/A	27	N/A
9/30/2014	169	-31	N/A	6	N/A
6/30/2014	141	-43	N/A	-13	N/A
3/31/2014	111	-52	N/A	-34	N/A
12/31/2013	86	-64	N/A	-44	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PCRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PCRX is expected to become profitable in the next 3 years.

Revenue vs Market: PCRX's revenue (0.6% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: PCRX's revenue (0.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PCRX's Return on Equity is forecast to be low in 3 years time (6.9%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 05:57
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacira BioSciences, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Balaji Prasad	Barclays
Anita Dushyanth	Berenberg

Pacira BioSciences Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 46% to US$20.83

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Consensus EPS estimates fall by 21%

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Price target decreased by 9.5% to US$55.89

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

Recent updates

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024

Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Pacira BioSciences, Inc. Announces Chief Financial Officer Changes

Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences

Investor sentiment improves as stock rises 15%

Pacira Biosciences, Inc. Announces Board Changes

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Investor sentiment deteriorates as stock falls 44%

CEO & Director recently bought US$100k worth of stock

Price target decreased by 46% to US$20.83

New major risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 20%

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures